메뉴 건너뛰기




Volumn 3, Issue 1, 2010, Pages 3-5

Antiplatelet therapy after percutaneous coronary intervention should another regimen be "TAPT?"

Author keywords

Angioplasty platelets; Cliostazol; Clopidogrel; Editorials; Platelet

Indexed keywords

ACETYLSALICYLIC ACID; CILOSTAZOL; CLOPIDOGREL; CYTOCHROME P450; OMEPRAZOLE; PRASUGREL; PROTON PUMP INHIBITOR; THIENOPYRIDINE DERIVATIVE; TICAGRELOR; WARFARIN;

EID: 77953676517     PISSN: 19417640     EISSN: 19417632     Source Type: Journal    
DOI: 10.1161/CIRCINTERVENTIONS.110.936948     Document Type: Editorial
Times cited : (6)

References (20)
  • 3
    • 65349083830 scopus 로고    scopus 로고
    • *3 polymorphisms are associated with high post-treatment platelet reactivity in Asian patients with acute coronary syndrome
    • *3 polymorphisms are associated with high post-treatment platelet reactivity in Asian patients with acute coronary syndrome. J Thromb Haemost. 2009;7:897-899.
    • (2009) J. Thromb. Haemost. , vol.7 , pp. 897-899
    • Kim, I.S.1    Choi, B.R.2    Jeong, Y.H.3    Kwak, C.H.4    Kim, S.5
  • 5
    • 77953662948 scopus 로고    scopus 로고
    • Clopidogrel and the optimization of gastrointestinal events (COGENT)
    • Presented at, San Francisco, CA
    • Bhatt D. Clopidogrel and the optimization of gastrointestinal events (COGENT), Presented at TCT, San Francisco, CA, 2009.
    • (2009) TCT
    • Bhatt, D.1
  • 6
    • 33748948717 scopus 로고    scopus 로고
    • Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting
    • Cuisset T, Frere C, Quilici J, Morange PE, Nait-Saidi L, Carvajal J, Lehmann A, Lambert M, Bonnet JL, Alessi MC. Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting. J Am Coll Cardiol. 2006;48:1339-1345.
    • (2006) J. Am. Coll. Cardiol. , vol.48 , pp. 1339-1345
    • Cuisset, T.1    Frere, C.2    Quilici, J.3    Morange, P.E.4    Nait-Saidi, L.5    Carvajal, J.6    Lehmann, A.7    Lambert, M.8    Bonnet, J.L.9    Alessi, M.C.10
  • 7
    • 17744376570 scopus 로고    scopus 로고
    • Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: Results from the ARMYDA-2 (antiplatelet therapy for reduction of myocardial damage during angioplasty) study
    • Patti G, Colonna G, Pasceri V, Pepe LL, Montinaro A, Di Sciascio G. Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study. Circulation. 2005;111:2099-2106.
    • (2005) Circulation , vol.111 , pp. 2099-2106
    • Patti, G.1    Colonna, G.2    Pasceri, V.3    Pepe, L.L.4    Montinaro, A.5    Di Sciascio, G.6
  • 8
    • 56949093392 scopus 로고    scopus 로고
    • Design and rationale of CURRENT-OASIS 7: A randomized, 2X2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy
    • e1081. Data presented at the European Society of Cardiology Meeting
    • Mehta SR, Bassand JP, Chrolavicius S, Diaz R, Fox KA, Granger CB, Jolly S, Rupprecht HJ, Widimsky P, Yusuf S. Design and rationale of CURRENT-OASIS 7: a randomized, 2X2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy. Am Heart J. 2008;156:1080-1088, e1081. Data presented at the European Society of Cardiology Meeting, 2009.
    • (2008) Am. Heart J. , vol.156 , pp. 1080-1088
    • Mehta, S.R.1    Bassand, J.P.2    Chrolavicius, S.3    Diaz, R.4    Fox, K.A.5    Granger, C.B.6    Jolly, S.7    Rupprecht, H.J.8    Widimsky, P.9    Yusuf, S.10
  • 10
    • 64549133799 scopus 로고    scopus 로고
    • Evaluation of individualized clopidogrel therapy after drug-eluting stent implantation in patients with high residual platelet reactivity: Design and rationale of the GRAVITAS trial
    • 824, e811
    • Price MJ, Berger PB, Angiolillo DJ, Teirstein PS, Tanguay JF, Kandzari DE, Cannon CP, Topol EJ. Evaluation of individualized clopidogrel therapy after drug-eluting stent implantation in patients with high residual platelet reactivity: design and rationale of the GRAVITAS trial. Am Heart J. 2009;157:818-824, 824, e811.
    • (2009) Am. Heart J. , vol.157 , pp. 818-824
    • Price, M.J.1    Berger, P.B.2    Angiolillo, D.J.3    Teirstein, P.S.4    Tanguay, J.F.5    Kandzari, D.E.6    Cannon, C.P.7    Topol, E.J.8
  • 11
    • 77953661111 scopus 로고    scopus 로고
    • Adding cilostazol to dual antiplatelet therapy achieves greater platelet inhibition than high maintenance-dose clopidogrel in patients with acute myocardial infarction: Results of the ACCEL-AMI study
    • Jeong YH, Kim IS, Park Y, Hwang SJ, Lee SW, Kwak CH, Park SW. Adding cilostazol to dual antiplatelet therapy achieves greater platelet inhibition than high maintenance-dose clopidogrel in patients with acute myocardial infarction: results of the ACCEL-AMI study. Circ Cardiovasc Interv. 2010;3:17-26.
    • (2010) Circ Cardiovasc Interv , vol.3 , pp. 17-26
    • Jeong, Y.H.1    Kim, I.S.2    Park, Y.3    Hwang, S.J.4    Lee, S.W.5    Kwak, C.H.6    Park, S.W.7
  • 12
    • 52449085759 scopus 로고    scopus 로고
    • A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: Results of the OPTIMUS-2 study
    • Angiolillo DJ, Capranzano P, Goto S, Aslam M, Desai B, Charlton RK, Suzuki Y, Box LC, Shoemaker SB, Zenni MM, Guzman LA, Bass TA. A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study. Eur Heart J. 2008;29:2202-2211.
    • (2008) Eur. Heart J. , vol.29 , pp. 2202-2211
    • Angiolillo, D.J.1    Capranzano, P.2    Goto, S.3    Aslam, M.4    Desai, B.5    Charlton, R.K.6    Suzuki, Y.7    Box, L.C.8    Shoemaker, S.B.9    Zenni, M.M.10    Guzman, L.A.11    Bass, T.A.12
  • 16
    • 62949165644 scopus 로고    scopus 로고
    • Cilostazol in addition to aspirin and clopidogrel improves long-term outcomes after percutaneous coronary intervention in patients with acute coronary syndromes: A randomized, controlled study
    • Han Y, Li Y, Wang S, Jing Q, Wang Z, Wang D, Shu Q, Tang X. Cilostazol in addition to aspirin and clopidogrel improves long-term outcomes after percutaneous coronary intervention in patients with acute coronary syndromes: a randomized, controlled study. Am Heart J. 2009;157:733-739.
    • (2009) Am. Heart J. , vol.157 , pp. 733-739
    • Han, Y.1    Li, Y.2    Wang, S.3    Jing, Q.4    Wang, Z.5    Wang, D.6    Shu, Q.7    Tang, X.8
  • 20
    • 77953667233 scopus 로고    scopus 로고
    • PLETAL cilostazol Package insert. Rockville, MD: Otsuka America Pharmaceuticals
    • PLETAL (cilostazol) [Package insert]. Rockville, MD: Otsuka America Pharmaceuticals; 2009.
    • (2009)


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.